Development of multi-epitope vaccines targeting wild-typesequence p53 peptides

References

• Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr. Cancer Drug Targets7, 633–642 (2007).
   PubMed Web of Science ®Google Scholar
• Morris LF, Ribas A. Therapeutic cancer vaccines. Surg. Oncol. Clin. N. Am.16, 819–831 (2007).
   Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor. Nat. Immunol.3, 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Nijman HW, Van der Burg SH. Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T cells. Immunol. Lett.40, 171–178 (1994).
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, DeLeo AB. p53 as an immuno-therapeutic target in head and neck cancer. Adv. Otorhinolargyngol.62, 151–160 (2005).
   Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science253, 49–53 (1991).
   PubMed Web of Science ®Google Scholar
• Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl Cancer Inst.88, 1442–1455 (1996).
   PubMed Web of Science ®Google Scholar
• Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2–11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res.63, 1188–1191 (2003).
   PubMed Web of Science ®Google Scholar
• De Leo AB. p53-based immunotherapy of cancer. Adv. Otorhinolaryngol.62, 134–150 (2005).
   Google Scholar
• Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc. Natl Acad. Sci. USA92, 11993–11997 (1995).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol.160, 328–333 (1998).
   PubMed Web of Science ®Google Scholar
• Ropke M, Hald J, Guldberg P et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl Acad. Sci. USA93, 14704–14707 (1996).
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Zwaveling S, Bos GMJ et al. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res.60, 5508–5513 (2000).
   PubMed Web of Science ®Google Scholar
• Allen PM. Making antigens presentable. J. Immunol.179, 3–4 (2007).
   Google Scholar
• Harding CV, Neefjes J. Antigen processing and recognition. Curr. Opin. Immunol.17, 55–57 (2005).
   Google Scholar
• Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin. Cancer Res.12, 3890–3895 (2006).
   PubMed Web of Science ®Google Scholar
• Toes RE, Ossendorp F, Offringa Melief CJM. CD4 T cells and their role in antitumor immune responses. J. Exp. Med.189, 753–756 (1999).
   PubMed Web of Science ®Google Scholar
• Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol.23, 5099–5107 (2005).
   PubMed Web of Science ®Google Scholar
• Nijman HW, Houbiers JG Vierboom MP et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol.23, 1215–1219 (1993).
   PubMedGoogle Scholar
• Chikamatsu K, Albers A, Stanson J et al. p53110–124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res.63, 3675–3681 (2003).
   PubMed Web of Science ®Google Scholar
• Ito D, Albers A, Zhao YX et al. The wild-type sequence (wt) p53(25–35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53264–272 peptide CD8+ T cells. J. Immunol.177, 6795–6803 (2006).
   PubMedGoogle Scholar
• Eura M, Chikamatsu K, Katsura F et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin. Cancer Res.6, 979–986 (2000).
   PubMedGoogle Scholar
• Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, DeLeo AB. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8+ T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin. Immunol.125, 43–51 (2007).
   PubMed Web of Science ®Google Scholar
• Theobald M, Ruppert T, Kuckelkorn U et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med.188, 1017–1028 (1998).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med.183, 1357–1365 (1996).
   PubMed Web of Science ®Google Scholar
• Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med.185, 833–841 (1997).
   PubMed Web of Science ®Google Scholar
• Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J. Immunol.164, 596–602 (2000).
   PubMed Web of Science ®Google Scholar
• Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med.186, 695–704 (1997).
   PubMed Web of Science ®Google Scholar
• Tuting T, Gambotto A, Robbins PD, Storkus WJ, DeLeo AB. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen b-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther.6, 629–636 (1999).
   Google Scholar
• Hernández J, Ko A, Sherman LA. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol.166, 3908–3914 (2001).
   PubMed Web of Science ®Google Scholar
• Cicinnati VR, Dworacki G, Albers A et al. Impact of p53-based immunization on primary chemically-induced tumors. Int. J. Cancer113, 961–970 (2005).
   Google Scholar
• Hoffmann TK, Donnenberg AD, Finkelstein SD et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53 264–272 peptide in the circulation of patients with head and neck cancer. Cancer Res.62, 3521–3529 (2002).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Lubin R, Roche B et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl Cancer Inst.88, 1228–1233 (1996).
   PubMedGoogle Scholar
• Hoffmann TK, Nakano K, Elder EM et al. Generation of T cells specific for the wild-type sequence p53264–272 peptide in cancer patients: implications for immunoselection of epitope loss variants. J. Immunol.165, 5938–5944 (2000).
   PubMed Web of Science ®Google Scholar
• Houbiers JG, van der Burg SH, van de Watering LM et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer72, 637–641 (1995).
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine20, A46–A51 (2002).
   PubMedGoogle Scholar
• Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res.13, 6301–6311 (2007).
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Tregs and rethinking cancer immunotherapy. J. Clin. Invest.117, 1167–1174 (2007).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Mechanisms and functional significance of tumor-induced dendritic cell differentiation in cancer. Nat. Rev. Immunol.4, 941–952 (2004).
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Nakano K, Storkus WJ et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res.5, 1281–1288 (1999).
   PubMed Web of Science ®Google Scholar
• Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand. J. Immunol.53, 357–364 (2001).
   PubMedGoogle Scholar
• Hoffmann TK, Loftus DJ, Nakano K et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53264–272 epitope. J. Immunol.168, 1338–1347 (2002).
   PubMed Web of Science ®Google Scholar
• Lauwen MM, Zwaveling S, de Quartel L et al. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res.68, 893–900 (2008).
   PubMedGoogle Scholar
• Fujita H, Senju S, Yokomizo H et al. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol.28, 305–316 (1998).
   Google Scholar
• Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother.54, 1072–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Vence L, Palucka AK, Fay JW et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA104, 20884–20889 (2007).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol.6, 345–352 (2005).
   PubMed Web of Science ®Google Scholar
• Arias RS, Flanagan ML, Miller KD et al. RA8, a human anti-CD25 antibody against human Treg cells. Hybridoma (Larchmt)26, 119–130 (2007).
   Google Scholar
• Morse MA, Hobeika AC, Osada T et al. Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood112(3), 610–618 (2008).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer120, 2723–2733 (2007).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother.56, 641–648 (2007).
   PubMed Web of Science ®Google Scholar
• Czystowska M, Szczepanski M, Szajnik M, Whiteside TL. IRX-2, a multi-targeted biologic, protects human T-cells from tumor-induced cell death. Presented at: American Association for Cancer Research, San Diego, CA, USA, 12–16 April 2008 (Abstract #2090).
   Google Scholar
• Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med.195, 1523–1532 (2002).
   PubMed Web of Science ®Google Scholar
• Nikitina EY, Clark JI, Van Beynen J et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res.7, 127–135 (2001).
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johnsen HE et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a Phase I study. Cancer Immunol. Immunother.53, 633–641 (2004).
   PubMed Web of Science ®Google Scholar
• Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother.56, 1485–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Herrin VE, Achtar MS, Steinberg SM et al. A randomized Phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. Presented at: American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007 (Abstract 3011).
   Google Scholar
• Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365–73 wild type peptide loaded on dendritic cells in vitro, specifically recognized and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand. J. Immunol.51, 128–133 (2000).
   PubMed Web of Science ®Google Scholar
• McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol. Immunother.49, 417–425 (2000).
   Google Scholar
• Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br. J. Cancer84, 1052–1057 (2001).
   PubMed Web of Science ®Google Scholar